|本期目录/Table of Contents|

[1]吴 莹,李学英,潘有福.BAP1及其对透明细胞肾细胞癌的抑制作用[J].遵义医科大学学报,2019,42(05):594-601.
 Wu Ying,Li Xueying,Pan Youfu.Research progress of BAP1 and its role on the inhibition of clear cell renal cell carcinoma[J].Journal of Zunyi Medical University,2019,42(05):594-601.





Research progress of BAP1 and its role on the inhibition of clear cell renal cell carcinoma
吴 莹李学英潘有福
(遵义医科大学 医学遗传学教研室暨贵州省基因检测与治疗特色重点实验室,贵州 遵义 563099)
Wu YingLi XueyingPan Youfu
(Department of Medical Genetics,Zunyi Medical University and Key Laboratory of Gene Detection and Treatment in Guizhou Province,Zunyi Medical University,Zunyi Guizhou 563099,China)
BAP1 透明细胞肾细胞癌 去泛素化
BRCA1-associated protein 1 clear cell renal cell carcinoma deubiquitination
肾癌在泌尿系统肿瘤中位居第三,其中约有80%的肾癌是透明细胞肾细胞癌(clear cell renal cell carcinoma,ccRCC)。BAP1(BRCA1-associated protein 1)是一个重要的肿瘤抑制因子,通过去泛素化作用发挥多方面的功能,如参与转录调控、表观遗传调控、DNA损伤修复等。最近,研究发现体细胞BAP1突变可能促成ccRCC细胞中程序性细胞死亡配体1(programmed cell death-Ligand 1,PD-L1)的表达。本文综述了BAP1的结构功能及BAP1突变在ccRCC发生发展中的作用的相关进展,以期深入了解ccRCC的发生发展机制。
Renal cell carcinoma ranks third in urinary tumors,about 80% of which is clear cell renal cell carcinoma(ccRCC).BRCA1-associated protein 1(BAP1)is an important tumor suppressor and plays multi-faceted functions through deubiquitination,such as transcriptional and epigenetic regulation and DNA damage repair.Recently,studies have found that somatic BAP1 mutations may contribute to the expression of programmed cell death-Ligand 1(PD-L1)in ccRCC cells.To further understand the mechanism of ccRCC development,this paper reviewed the structural and functional aspects of BAP1 and the roles of BAP1 mutation on the occurrence and development of ccRCC.


[1] Siegel R L,Miller K D,Jemal A.Cancer statistics,2018[J].CA Cancer J Clin,2018,68(1):7-30. [2] Hsieh J J,Purdue M P,Signoretti S,et al.Renal cell carcinoma[J].Nat Rev Dis Primers,2017,3:1-42. [3] 陈金东.转移性肾癌的临床治疗研究进展[J].遵义医学院学报,2015,38(3):201-208. [4] 陈金东.肾癌遗传学研究进展[J].遵义医学院学报,2014,37(2):132-137. [5] 赵玥,吴瑾.转移性肾癌的内科治疗及相关研究进展[J].癌症进展,2018,16(7):807-811. [6] Joosten S C,Hamming L,Soetekouw P M,et al.Resistance to sunitinib in renal cell carcinoma:From molecular mechanisms to predictive markers and future perspectives[J].Biochim Biophys Acta,2015,1855(1):1-16. [7] Mattei J,da Silva R D,Sehrt D,et al.Targeted therapy in metastatic renal carcinoma[J].Cancer Lett,2014,343(2):156-160. [8] 刘长姣,李明春.肾癌靶向治疗及联合用药的研究进展[J].中国医院药学杂志,2017,37(7):666-669. [9] 郭晓强,张巧霞.肾细胞癌的分子机制和药物治疗进展[J].遵义医学院学报,2016,39(1):100-106. [10]Murali R,Wiesner T,Scolyer R A.Tumours associated with BAP1 mutations[J].Pathology,2013,45(2):116-126. [11]Piva F,Giulietti M,Occhipinti G,et al.Computational analysis of the mutations in BAP1,PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma[J].Oncotarget,2015,6(31):32161-32168. [12]Brugarolas J.PBRM1 and BAP1 as novel targets for renal cell carcinoma[J].Cancer J,2013,19(4):324-332. [13]Dai F,Lee H,Zhang Y,et al.BAP1 inhibits the ER stress gene regulatory network and modulates metabolic stress response[J].Proc Natl Acad Sci U S A,2017,114(12):3192-3197. [14]Okino Y,Machida Y,Frankland-Searby S,et al.BRCA1-associated protein 1(BAP1)deubiquitinase antagonizes the ubiquitin-mediated activation of foxK2 target genes[J].J Biol Chem,2015,290(3):1580–1591. [15]Yu M,Liang H,Fu Z,et al.BAP1 suppresses lung cancer progression and is inhibited by miR-31[J].Oncotarget,2016,7(12):13742-13753. [16]Komander D,Clague M J,Urbé S.Breaking the chains:structure and function of the deubiquitinases[J].Nat Rev Mol Cell Bio,2009,10(8):550-563. [17]Eletr Z M,Wilkinson K D.Regulation of proteolysis by human deubiquitinating enzymes[J].Biochim Biophys Acta,2014,1843(1):114-128. [18]Yu J,Chen W L.Research advances on ubiquitin C-terminal hydrolase in oncogenesis and progression[J].Journal of Zhejiang University(Medical Sciences),2015,44(2):217-222. [19]Seliger B,Fedorushchenko A,Brenner W,et al.Ubiquitin COOH-terminal hydrolase 1:A biomarker of renal cell carcinoma associated with enhanced tumor cell proliferation and migration[J].Clin Cancer Res,2007,13(1):27-37. [20]Rolen U,Kobzeva V,Gasparjan N,et al.Activity profiling of deubiquitinating enzymes in cervical carcinoma biopsies and cell lines[J].Mol Carcinog,2006,45(4):260-269. [21]Miyoshi Y,Nakayama S,Torikoshi Y,et al.High expression of ubiquitin carboxy-terminal hydrolase-L1 and -L3 mRNA predicts early recurrence in patients with invasive breast cancer[J].Cancer Sci,2006,97(6):523-529. [22]Harbour J W,Onken M D,Roberson E D O,et al.Frequent mutation of BAP1 in metastasizing uveal melanomas[J].Science,2010,330(6009):1410-1413. [23]Wei R,Liu X,Yu W,et al.Deubiquitinases in cancer[J].Oncotarget,2015,6(15):12872-12889. [24]Brugarolas J.Molecular genetics of clear-cell renal cell carcinoma[J].J Clin Oncol,2014,32(18):1968-1976. [25]Pan H,Jia R,Zhang L,et al.BAP1 regulates cell cycle progression through E2F1 target genes and mediates transcriptional silencing via H2A monoubiquitination in uveal melanoma cells[J].Int J Biochem Cell Biol,2015,60:176-184. [26]Zhou W,Wang X,Rosenfeld M G.Histone H2A ubiquitination in transcriptional regulation and DNA damage repair[J].Int J Biochem Cell Biol,2009,41(1):12-15. [27]Mehdi A,Riazalhosseini Y.Epigenome aberrations:emerging driving factors of the clear cell renal cell carcinoma[J].Int J Mol Sci,2017,18(8):1774. [28]Bott M,Brevet M,Taylor B S,et al.The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma[J].Nat Genet,2011,43(7):668-672. [29]Riazalhosseini Y,Lathrop M.Precision medicine from the renal cancer genome[J].Nat Rev Nephrol,2016,12(11):655-666. [30]Jensen D E,Proctor M,Marquis S T,et al.BAP1:a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression[J].Oncogene,1998,16(9):1097-1112. [31]李则,任尊,涂鸿鹄,等.BAP1及其抑癌作用研究新进展[J].上海交通大学学报(医学版),2017,37(5):689-693. [32]Bott M,Brevet M,Taylor B S,et al.The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma[J].Nat Genet,2011,43(7):668–672. [33]Qin J,Zhou Z,Chen W,et al.BAP1 promotes breast cancer cell proliferation and metastasis by deubiquitinating KLF5[J].Nat Commun,2015,6:1-12. [34]Kumar R,Taylor M,Miao B,et al.BAP1 plays a survival role in cutaneous melanoma[J].J Invest Dermatol,2015,135(4):1089–1097. [35]Asada S,Goyama S,Inoue D,et al.Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis[J].Nat Commun,2018,9(1):2733-2750. [36]Peng H,Prokop J,Karar J,et al.Familial and somatic BAP1 mutations inactivate ASXL1/2-mediated allosteric regulation of BAP1 deubiquitinase by targeting multiple independent domains[J].Cancer Res,2018,78(5):1200-1213. [37]Hebert L,Bellanger D,Guillas C,et al.Modulating BAP1 expression affects ROS homeostasis,cell motility and mitochondrial function[J].Oncotarget,2017,8(42):72513-72527. [38]Campagne A,Zielinski D,Michaud A,et al.The BAP1 deubiquitinase complex is a general transcriptional co-activator[J].Bio Rxiv,2018:1-31. [39]Daou S,Hammond-Martel I,Mashtalir N,et al.The BAP1/ASXL2 histone H2A deubiquitinase complex regulates cell proliferation and is disrupted in cancer[J].J Biol Chem,2015,290(48):28643-28663. [40]Sahtoe D D,Van Dijk W J,Ekkebus R,et al.BAP1/ASXL1 recruitment and activation for H2A deubiquitination[J].Nat Commun,2016,7:1-13. [41]Peng H,Prokop J,Karar J,et al.PD46-01 BAP1 deubiquitinase isallosterically regulated by ASXL1/2:sometic BAP1 mutation in RCC and other tumors inactive this regulation by targeting multiple multiple independent domains[J].J Urol,2018,199(4):1. [42]Ji Z,Mohammed H,Webber A,et al.The forkhead transcription factor FOXK2 acts as a chromatin targeting factor for the BAP1-containing histone deubiquitinase complex[J].Nucleic Acids Res,2014,42(10):6232-6242. [43]Carbone M,Yang H,Pass H I,et al.BAP1 and cancer[J].Nat Rev Cancer,2013,13(3):153-159. [44]Yu H,Mashtalir N,Daou S,et al.The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression[J].Mol Cell Biol,2010,30(21):5071-5085. [45]Ben-Hamo R,Efroni S.MicroRNA-gene association as a prognostic biomarker in cancer exposes disease mechanisms[J].Plos Comput Biol,2013,9(11):e1003351. [46]Ge Y Z,Xu L W,Zhou C C,et al.A BAP1 Mutation-specific MicroRNA Signature Predicts Clinical Outcomes in Clear Cell Renal Cell Carcinoma Patients with Wild-type BAP1[J].J Cancer,2017,8(13):2643-2652. [47]Yu H,Pak H,Hammond-Martel I,et al.Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair[J].Proc Natl Acad Sci USA,2014,111(1):285-290. [48]Eletr Z M,Yin L,Wilkinson K D,et al.BAP1 is phosphorylated at serine 592 in S-phase following DNA damage[J].Febs Lett,2013,587(24):3906-3911. [49]马楠,曾赵军.乳腺癌易感蛋白1在DNA损伤修复中的作用[J].生命的化学,2011,31(2):222-226. [50]Chapman J R,Taylor M R G,Boulton S J.Playing the end game:DNA double-strand break repair pathway choice[J].Mol Cell,2012,47(4):497-510. [51]Butler L R,Densham R M,Jia J,et al.The proteasomal de‐ubiquitinating enzyme POH1 promotes the double‐strand DNA break response[J].Embo J,2012,31(19):3918-3934. [52]Wang S S,Gu Y F,Wolff N,et al.Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis[J].Proc Natl Acad Sci USA,2014,111(46):16538-16543. [53]Popova T,Hebert L,Jacquemin V,et al.Germline BAP1 mutations predispose to renal cell carcinomas[J].Am J Hum Genet,2013,92(6):974-980. [54]Pena-Llopis S,Vega-Rubin-de-Celis S,Liao A,et al.BAP1 loss defines a new class of renal cell carcinoma[J].Nat Genet,2012,44(7):751-759. [55]Guo G,Gui Y,Gao S,et al.Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma[J].Nat Genet,2012,44(1):17-19. [56]Hakimi A A,Ostrovnaya I,Reva B A,et al.Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2:a report by MSKCC and the KIRC TCGA research network[J].Clin Cancer Res,2013,19(12):3259-3267. [57]Testa J R,Cheung M,Pei J,et al.Germline BAP1 mutations predispose to malignant mesothelioma[J].Nat Genet,2011,43(10):1022-1025. [58]Mochel M C,Piris A,Nose V,et al.Loss of BAP1 expression in basal cell carcinomas in patients with germline BAP1 mutations[J].Am J Clin Pathol,2015,143(6):901-904. [59]Horton C,LaDuca H,Reineke P.BAP1 tumor predisposition syndrome:preliminary data from a laboratory-based multigene panel testing cohort[J].J Clin Oncol,2017,35(6):490-490. [60]Kluzek K,Srebniak M I,Majer W,et al.Genetic characterization of Polish ccRCC patients:somatic mutation analysis of PBRM1,BAP1 and KDMC5,genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNA[J].Oncotarget,2017,8(17):28558-28574. [61]Gerlinger M,Horswell S,Larkin J,et al.Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing[J].Nat Genet,2014,46(3):225-233. [62]陈金东.肾癌敲基因小鼠模型建立及应用的研究进展[J].遵义医学院学报,2017,40(4):347-357. [63]Varela I,Tarpey P,Raine K,et al.Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma[J].Nature,2011,469(7331):539-542. [64]Gao W,Li W,Xiao T,et al.Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-/- clear cell renal carcinoma[J].Proc Natl Acad Sci USA,2017,114(5):1027-1032. [65]Gu Y F,Cohn S,Christie A,et al.Modeling renal cell carcinoma in mice:Bap1 and Pbrm1 inactivation drive tumor grade[J].Cancer Discov,2017,7(8):900-917. [66]Kapur P,Peña-Llopis S,Christie A,et al.Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma:a retrospective analysis with independent validation[J].Lancet Oncol,2013,14(2):159-167. [67]Ventii K H,Devi N S,Friedrich K L,et al.BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization[J].Cancer Res,2008,68(17):6953-6962. [68]Kuznetsov J N,Aguero T,Kurtenbach S,et al.The tumor suppressor BAP1 promotes a developmental switch from pluripotency to differentiation[J].Cancer Res,2017,77(13):1541. [69]Machida Y J,Machida Y,Vashisht A A,et al.The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1[J].J Biol Chem,2009,284(49):34179-34188. [70]Eletr Z M,Wilkinson K D.An emerging model for BAP1's role in regulating cell cycle[J].Cell Biochem Biophys,2011,60(1-2):3-11. [71]Creighton C J,Morgan M,Gunaratne P H,et al.Comprehensive molecular characterization of clear cell renal cell carcinoma[J].Nature,2013,499(7456):43-49. [72]Wang J,Xi Z,Xi J,et al.Somatic mutations in renal cell carcinomas from Chinese patients revealed by whole exome sequencing[J].Cancer Cell Int,2018,18(159):1-12. [73]李岚,宋启斌,刘立柏.PD-L1表达调控研究进展[J].肿瘤学杂志,2019,25(3):185-191.



[基金项目]国家自然科学基金资助项目(NO:31760321); 遵义医学院遗传学扶持学科建设项目(NO:4009403-0001)。 [通信作者]李学英,女,硕士,教授,硕士生导师,研究方向:肿瘤分子生物学,E-mail:leexueying4722@163.com; 潘有福,男,博士,教授,研究方向:肿瘤分子生物学,E-mail:panyf9@sina.com。
更新日期/Last Update: 2019-10-25